Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies

Tumor Biology

Volumn 32, Issue 1, 2011, Pages 13-22

  Molina, Rafael ^h   Alvarez, Elias ^a   Aniel Quiroga, Angeles ^b   Borque, Maria ^c   Candás, Belen ^d   Leon, Antonio ^e   Poyatos, Rafael M ^f   Gelabert, Montserrat ^g  

^a HOSPITAL XERAL CALDE   (Spain)

^b HOSPITAL DE CRUCES   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^g Novartis   (Spain)

^h NONE

Author keywords

Cromogranin A; False positive; Method comparison; Neuroendocrine tumors; Tumor markers

Indexed keywords

CHROMOGRANIN A;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTROCYTOMA; BLADDER CANCER; BREAST CANCER; CANCER STAGING; COLON CARCINOMA; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENDOMETRIUM CANCER; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SPECIFICITY; FEMALE; HEART FAILURE; HUMAN; HYPERTENSION; IMMUNORADIOMETRIC ASSAY; INTERMETHOD COMPARISON; LIVER CANCER; LIVER DISEASE; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; NEUROENDOCRINE TUMOR; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN PURIFICATION; RADIOIMMUNOASSAY; RECTUM CARCINOMA; SARCOMA; SENSITIVITY AND SPECIFICITY; STOMACH DISEASE;

EID: 78751510658     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-010-0085-x     Document Type: Article

References (49)

1. EW McDermott B Guduric MF Brennan 1994 Prognostic variables in patients with gastrointestinal carcinoid tumours Br J Surg 81 1007 1009 1:STN:280:DyaK2M%2Fgs1egug%3D%3D 10.1002/bjs.1800810725 7922047 (Pubitemid 24230096)
2. J Soga 2003 Carcinoids and their variant endocrinomas. An analysis of 11842 reported cases J Exp Clin Cancer Res 22 517 530 1:STN:280: DC%2BD2c7lvFCrsA%3D%3D 15053292
3. ED Williams M Sandler 1963 The classification of carcinoid tumours Lancet 1 238 239 1:STN:280:DyaF387pt1OgtQ%3D%3D 10.1016/S0140-6736(63)90951-6 14000847
4. LJ Deftos 1991 Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker Endocr Rev 12 181 187 1:CAS:528:DyaK3MXlslCksLw%3D 10.1210/edrv-12-2-181 2070778
5. Oberg N, Stridsberg M. Neuroendocrine tumors. In: Diamandis EP, Fritsche HA, Lilja H, Chan DW, Schwartz MK, editors. Tumor markers: physiology, pathobiology, technology and clinical applications. Washington: American Association for Clinical Chemistry Press; 2002. p. 339-50.
6. D Campana F Nori L Piscitelli AM Morselli-Labate R Pezzilli R Corinaldesi P Tomassetti 2007 Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol 25 1967 1973 1:CAS:528:DC%2BD2sXmvVWmsro%3D 10.1200/JCO.2006.10.1535 17513802 (Pubitemid 46972778)
7. E Bajetta L Ferrari A Martinetti L Celio G Procopio S Artale, et al. 1999 Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors Cancer 86 858 865 1:STN:280:DyaK1MzptlCgtQ%3D%3D 10.1002/(SICI)1097- 0142(19990901)86:5<858::AID-CNCR23>3.0.CO;2-8 10463986 (Pubitemid 29399927)
8. S Bashir F Gibril JV Ojeaburu B Asgharian LK Entsuah G Ferraro, et al. 2002 Prospective study of the ability of histamine, serotonin or serum chromogranin A levels to identify gastric carcinoids in patients with gastrinomas Aliment Pharmacol Ther 16 1367 1382 1:CAS:528:DC%2BD38XntVCjs70%3D 10.1046/j.1365-2036.2002.01249.x 12144588
9. M Cimitan A Buonadonna R Cannizzaro V Canzonieri E Borsatti R Ruffo L De Apollonia 2003 Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role Ann Oncol 14 1135 1141 1:STN:280:DC%2BD3szitlCqsQ%3D%3D 10.1093/annonc/mdg279 12853358 (Pubitemid 36950180)
10. B Eriksson H Arnberg PG Lindgren LE Lorelius A Magnusson G Lundqvist, et al. 1990 Neuroendocrine pancreatic tumours: clinical presentation, biochemical and histopathological findings in 84 patients J Intern Med 228 103 113 1:STN:280:DyaK3czmvFaltw%3D%3D 10.1111/j.1365-2796.1990.tb00202.x 2168468
11. B Eriksson K Oberg M Stridsberg 2000 Tumor markers in neuroendocrine tumors Digestion 62 Suppl 1 33 38 1:CAS:528:DC%2BD3cXmtVaku7w%3D 10.1159/000051853 10940685
12. D Granberg M Stridsberg R Seensalu B Eriksson G Lundqvist K Oberg B Skogseid 1999 Plasma chromogranin A in patients with multiple endocrine neoplasia type 1 J Clin Endocrinol Metab 84 2712 2717 1:CAS:528: DyaK1MXltFClsbg%3D 10.1210/jc.84.8.2712 10443665 (Pubitemid 30641998)
13. D Nehar C Lombard-Bohas S Olivieri B Claustrat JA Chayvialle MC Penes, et al. 2004 Interest of chromogranin A for diagnosis and follow-up of endocrine tumours Clin Endocrinol 60 644 652 1:CAS:528:DC%2BD2cXltFWqu78%3D 10.1111/j.1365-2265.2004.02030.x (Oxf) (Pubitemid 38669857)
14. FR Nobels DJ Kwekkeboom W Coopmans CH Schoenmakers J Lindemans WW De Herder, et al. 1997 Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones J Clin Endocrinol Metab 82 2622 2628 1:CAS:528:DyaK2sXltFGmsrc%3D 10.1210/jc.82.8.2622 9253344 (Pubitemid 27337883)
15. E Seregni L Ferrari E Bajetta A Martinetti E Bombardieri 2001 Clinical significance of blood chromogranin A measurement in neuroendocrine tumours Ann Oncol 12 Suppl 2 S69 72 10.1023/A:1012434005852 11762355
16. M Stridsberg B Eriksson K Oberg ET Janson 2003 A comparison between three commercial kits for chromogranin A measurements J Endocrinol 177 337 341 1:CAS:528:DC%2BD3sXktlyntbY%3D 10.1677/joe.0.1770337 12740022 (Pubitemid 36656407)
17. P Tomassetti M Migliori P Simoni R Casadei R De Iasio R Corinaldesi L Gullo 2001 Diagnostic value of plasma chromogranin A in neuroendocrine tumours Eur J Gastroenterol Hepatol 13 55 58 1:STN:280:DC%2BD3M7nvVKlsg%3D%3D 10.1097/00042737-200101000-00010 11204811 (Pubitemid 32099569)
18. K Borch M Stridsberg P Burman JF Rehfeld 1997 Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis Scand J Gastroenterol 32 198 202 1:STN:280: DyaK2s3jvFOqsQ%3D%3D 10.3109/00365529709000194 9085454
19. MP Canale EL Bravo 1994 Diagnostic specificity of serum chromogranin-A for pheochromocytoma in patients with renal dysfunction J Clin Endocrinol Metab 78 1139 1144 1:STN:280:DyaK2c3jtVKrsg%3D%3D 10.1210/jc.78.5.1139 8175970 (Pubitemid 24143037)
20. C Ceconi R Ferrari T Bachetti C Opasich M Volterrani B Colombo, et al. 2002 Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality Eur Heart J 23 967 974 1:CAS:528:DC%2BD38XlvFWisbw%3D 10.1053/euhj.2001.2977 12069452 (Pubitemid 35203876)
21. R Fossmark CS Jianu TC Martinsen G Qvigstad U Syversen HL Waldum 2008 Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition Scand J Gastroenterol 43 20 24 1:CAS:528:DC%2BD1cXhtF2kuw%3D%3D 10.1080/00365520701561959 18938772
22. M Giusti M Sidoti C Augeri C Rabitti F Minuto 2004 Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man Eur J Endocrinol 150 299 303 1:CAS:528: DC%2BD2cXivFCktrg%3D 10.1530/eje.0.1500299 15012614 (Pubitemid 38443779)
23. BI Hirschowitz J Worthington J Mohnen M Haber 2007 Chromogranin A in patients with acid hypersecretion and/or hypergastrinaemia Aliment Pharmacol Ther 26 869 878 1:CAS:528:DC%2BD2sXhtFKns7jM 10.1111/j.1365-2036.2007.03439.x 17767471 (Pubitemid 47346715)
24. DT O'Connor MR Pandlan E Carlton JH Cervenka RJ Hslao 1989 Rapid radioimmunoassay of circulating chromogranin A: in vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure Clin Chem 35 1631 1637 2547534
25. M Peracchi C Gebbia G Basilisco M Quatrini C Tarantino C Vescarelli, et al. 2005 Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids Eur J Endocrinol 152 443 448 1:CAS:528:DC%2BD2MXivVCksro%3D 10.1530/eje.1.01862 15757862 (Pubitemid 40439498)
26. S Sanduleanu M Stridsberg D Jonkers W Hameeteman I Biemond G Lundqvist, et al. 1999 Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study Aliment Pharmacol Ther 13 145 153 1:CAS:528:DyaK1MXitVeksbk%3D 10.1046/j.1365-2036.1999.00466.x 10102943 (Pubitemid 29090008)
27. MA Takiyyuddin RJ Parmer MT Kailasam JH Cervenka B Kennedy MG Ziegler, et al. 1995 Chromogranin A in human hypertension Influence Heredity Hypertens 26 213 220 1:STN:280:DyaK2MzjtFymsQ%3D%3D
28. HL Waldum JS Arnestad E Brenna I Eide U Syversen AK Sandvik 1996 Marked increase in gastric acid secretory capacity after omeprazole treatment Gut 39 649 653 1:CAS:528:DyaK2sXnsVegsg%3D%3D 10.1136/gut.39.5.649 9026477
29. Houben P, Lundqvist G, Biedmond I, Jonkers D, Stockbrugger R. 24 hour intragastric ph, basal and meal-stimulated serum gastrin and plasma chromogranin A after short term acid inhibition. Gastroenterology. 1997;112 A 152.
30. GM Portela-Gomes M Stridsberg 2001 Selective processing of chromogranin A in the different islet cells in human pancreas J Histochem Cytochem 49 483 490 1:CAS:528:DC%2BD3MXivFKgtr8%3D 11259451
31. M Stridsberg U Hellman E Wilander G Lundqvist K Hellsing K Oberg 1993 Fragments of chromogranin A are present in the urine of patients with carcinoid tumours: development of a specific radioimmunoassay for chromogranin A and its fragments J Endocrinol 139 329 337 1:CAS:528:DyaK2cXnsVCqsw%3D%3D 10.1677/joe.0.1390329 8308469
32. MC Zatelli M Torta A Leon MR Ambrosio M Gion P Tomassetti, et al. 2007 Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study Endocr Relat Cancer 14 473 482 1:CAS:528:DC%2BD2sXhtV2lsrrN 10.1677/ERC-07-0001 17639060 (Pubitemid 47242645)
33. E Baudin JM Bidart A Bachelot M Ducreux D Elias P Ruffie M Schlumberger 2001 Impact of chromogranin A measurement in the work-up of neuroendocrine tumors Ann Oncol 12 Suppl 2 S79 82 10.1023/A:1012494309486 11762357
34. G Schurmann U Raeth B Wiedenmann H Buhr C Herfarth 1992 Serum chromogranin A in the diagnosis and follow-up of neuroendocrine tumors of the gastroenteropancreatic tract World J Surg 16 697 701 1:STN:280: DyaK3s%2FjtlGhtQ%3D%3D 10.1007/BF02067361 1413839
35. L Taupenot KL Harper DT O'Connor 2003 The chromogranin-secretogranin family N Engl J Med 348 1134 1149 1:CAS:528:DC%2BD3sXit1Smur4%3D 10.1056/NEJMra021405 12646671 (Pubitemid 36337325)
36. GP Bernini A Moretti M Ferdeghini S Ricci C Letizia E D'Erasmo, et al. 2001 A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours Br J Cancer 84 636 42 1:CAS:528:DC%2BD3MXisVerurk%3D 10.1054/bjoc.2000.1659 11237384 (Pubitemid 32238997)
37. DF Orr T Chen AH Johnsen R Chalk KD Buchanan JM Sloan, et al. 2002 The spectrum of endogenous human chromogranin A-derived peptides identified using a modified proteomic strategy Proteomics 2 1586 1600 1:CAS:528: DC%2BD38XpsVOmsrw%3D 10.1002/1615-9861(200211)2:11<1586::AID-PROT1586>3.0. CO;2-K 12442257 (Pubitemid 35424505)
38. L Ferrari E Seregni G Lucignani E Bajetta A Martinetti G Aliberti, et al. 2004 Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors Int J Biol Markers 19 295 304 1:STN:280:DC%2BD2M%2FitVGrtg%3D%3D 15646836
39. CF Mountain 2002 Staging classification of lung cancer. A critical evaluation Clin Chest Med 23 103 121 10.1016/S0272-5231(03)00063-7 11901906 (Pubitemid 34207765)
40. RA Stahel R Ginsberg K Haveman K Havemann FR Hirsch DC Ihde J Jassem 1989 Staging and prognostic factors in small cell lung cancer: a consensus report Lung Cancer 5 119 126 10.1016/0169-5002(89)90156-6
41. Petterson F. Annual report on the results of treatment in gynecologic cancer, vol. 20. Stockholm: FIGO ed; 1988.
42. ER De Long DM De Long DL Clarke-Pearson 1988 Comparing the areas under two or more correlated receiver operating characteristics curves: a non-parametric approach Biometrics 44 837 845 10.2307/2531595
43. C Stephan S Wesseling T Schink K Jung 2003 Comparison of eight computer programs for receiver-operating characteristics analysis Cl Chem 49 433 439 1:CAS:528:DC%2BD3sXhvFSksLk%3D 10.1373/49.3.433 (Pubitemid 36250204)
44. JD Fisher 1972 New York Heart Association Classification Arch Intern Med 129 836 1:STN:280:DyaE387osVSqsg%3D%3D 10.1001/archinte.129.5.836b 5025908
45. SW Lamberts LJ Hofland FR Nobels 2001 Neuroendocrine tumor markers Front Neuroendocrinol 22 309 339 1:CAS:528:DC%2BD3MXnt1OktL0%3D 10.1006/frne.2001.0218 11587555 (Pubitemid 33010744)
46. DJ Rozansky H Wu K Tang RJ Parmer DT O'Connor 1994 Glucocorticoid activation of chromogranin A gene expression. Identification and characterization of a novel glucocorticoid response element J Clin Invest 94 2357 2368 1:CAS:528:DyaK2MXisFWhurY%3D 10.1172/JCI117601 7989592
47. A Leon M Torta R Dittadi UE degli MR Ambrosio FG Delle, et al. 2005 Comparison between two methods in the determination of circulating chromogranin A in neuroendocrine tumors (NETs): results of a prospective multicenter observational study Int J Biol Markers 20 156 168 1:CAS:528:DC%2BD28XnsA%3D%3D 16240843
48. F Degorce Y Goumon L Jacquemart C Vidaud L Bellanger D Pons-Anicet, et al. 1999 A new human chromogranin A (CgA) immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145-245) Br J Cancer 79 65 71 1:CAS:528:DyaK1MXmvVKlug%3D%3D 10.1038/sj.bjc.6690013 10408695 (Pubitemid 28566928)
49. E Bajetta L Ferrari G Procopio L Catena E Ferrario A Martinetti, et al. 2002 Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours Ann Oncol 13 614 621 1:STN:280:DC%2BD38zhsVymsg%3D%3D 10.1093/annonc/mdf064 12056713 (Pubitemid 34461146)